Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.54 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.54 |
| ▸ | VSIR | Q9H7M9 | 3/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 3/20 | 0.39 |
| ▸ | CTSD | P07339 | 2/20 | 0.39 |
| ▸ | ECE1 | P42892 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5998197 | 0.97 | CD274 (0.57) | CD274PDCD1LG2VSIRMMEPDCD1 | |
| SCHEMBL8528144 | 0.97 | CD274 (0.57) | CD274PDCD1LG2VSIRMMEPDCD1 | |
| SCHEMBL29572216 | 0.97 | CD274 (0.57) | CD274PDCD1LG2VSIRMMEPDCD1 | |
| SCHEMBL29572257 | 0.97 | CD274 (0.57) | CD274PDCD1LG2VSIRMMEPDCD1 | |
| SCHEMBL30390006 | 0.94 | CD274 (0.52) | CD274PDCD1LG2VSIRMMEPDCD1 | |
| SCHEMBL29697048 | 0.94 | CD274 (0.49) | CD274PDCD1LG2VSIRMMEPDCD1 | |
| SCHEMBL29369310 | 0.91 | CD274 (0.52) | CD274PDCD1LG2VSIRMMEPDCD1 | |
| SCHEMBL30390127 | 0.90 | PDCD1LG2 (0.49) | CD274PDCD1LG2 | |
| SCHEMBL29630699 | 0.89 | ECE1 (0.51) | CD274PDCD1LG2BACE1CTSDECE1 | |
| SCHEMBL30390484 | 0.89 | CD274 (0.61) | CD274PDCD1LG2VSIRMMEPDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748447-A2 | INFLUENZA VIRUS VACCINES AND USES THEREOF | Icahn School of Medicine at Mount Sinai (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122080168-A | Bovine FSH recombinant protein, recombinant expression vector and preparation method thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4241785-B1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | ICAHN SCHOOL MED MOUNT SINAI (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260001918-A1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4370150-A1 | OVERCOMING ANTIBODY-INTERFERENCE IN AVIANS | Intervet International B.V. (NL) | 2024-05-22 | — | — | EP | disclosed |
| EP-4241785-A2 | INFLUENZA VIRUS VACCINES AND USES THEREOF | Icahn School of Medicine at Mount Sinai (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-2758075-B1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-05-03 | — | — | EP | disclosed |
| WO-2023285489-A1 | OVERCOMING ANTIBODY-INTERFERENCE IN AVIANS | INTERVET INTERNATIONAL B.V. (NL) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001918-A1 | INFLUENZA VIRUS VACCINES AND USES THEREOF | CD44, SIGLEC7, SIGLEC9 | CD274 2979/4885PDCD1LG2 3701/4885VSIR 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.